CSF3R As a Potential Prognostic Biomarker and Immunotherapy Target in Glioma

Overview

Journal Cent Eur J Immunol

Publisher Termedia

Specialty Allergy & Immunology

Date 2024 Oct 9

PMID 39381559

Authors

Minglei Huang

Longze Zhang

Yan Wu

Xue Zhou

Yanyang Wang

Jidong Zhang

Ye Liu

Zhixu He

Xianyao Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Gliomas are the most common malignant brain tumors, with complicated etiology and poor prognosis. However, there is still a lack of specific biomarkers for the diagnosis, treatment and prognosis assessment for glioma patients. Hence, the purpose of this study was to screen biomarkers for prognostic assessment and therapeutic interventions in gliomas.

Material And Methods: We utilized The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases to investigate the role of colony-stimulating factor 3 receptor (CSF3R) in glioma. Data analysis was conducted using R, GEPIA 2, TISCH and DepMap.

Results: CSF3R was up-regulated in glioma and associated with the clinical pathological features of the patients. Kaplan-Meier survival analysis indicated a significant association between the expression of CSF3R and prognosis in patients. Univariate and multivariate Cox analyses revealed that patients with high expression of CSF3R have a worse prognosis, and the expression of CSF3R was an independent prognostic factor in gliomas. The nomogram constructed based on the expression of CSF3R demonstrated lower 1-, 3-, and 5-year overall survival (OS) in patients with high CSF3R expression. The biological functional analysis of CSF3R demonstrated its association with various immune regulatory signals. Furthermore, CSF3R was linked to the expression of immune checkpoints and resistance to immunotherapy. Notably, CSF3R was predominantly detected in monocytes/macrophages.

Conclusions: Our study suggested that CSF3R might potentially function as an independent prognostic factor for glioma and hold promise as a biomarker and target for immunotherapy in glioma.

References

Cahill D, Turcan S . Origin of Gliomas. Semin Neurol. 2018; 38(1):5-10. DOI: 10.1055/s-0037-1620238. View

Dong F, Brynes R, Tidow N, Welte K, Lowenberg B, Touw I . Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995; 333(8):487-93. DOI: 10.1056/NEJM199508243330804. View

Zheng Y, Graeber M . Microglia and Brain Macrophages as Drivers of Glioma Progression. Int J Mol Sci. 2022; 23(24). PMC: 9779147. DOI: 10.3390/ijms232415612. View

Anderson N, Minutolo N, Gill S, Klichinsky M . Macrophage-Based Approaches for Cancer Immunotherapy. Cancer Res. 2020; 81(5):1201-1208. DOI: 10.1158/0008-5472.CAN-20-2990. View

Li T, Li J, Chen Z, Zhang S, Li S, Wageh S . Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions. J Control Release. 2022; 352:338-370. DOI: 10.1016/j.jconrel.2022.09.065. View

Wei J, Chen P, Gupta P, Ott M, Zamler D, Kassab C . Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2019; 22(2):180-194. PMC: 7442334. DOI: 10.1093/neuonc/noz212. View

Ceccarelli M, Barthel F, Malta T, Sabedot T, Salama S, Murray B . Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016; 164(3):550-63. PMC: 4754110. DOI: 10.1016/j.cell.2015.12.028. View

Singhal A, Subramanian M . Colony stimulating factors (CSFs): Complex roles in atherosclerosis. Cytokine. 2017; 122:154190. DOI: 10.1016/j.cyto.2017.10.012. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

10.

Lv K, Cao X, Wang R, Du P, Fu J, Geng D . Neuroplasticity of Glioma Patients: Brain Structure and Topological Network. Front Neurol. 2022; 13:871613. PMC: 9136300. DOI: 10.3389/fneur.2022.871613. View

11.

Zhu H, Hu X, Feng S, Gu L, Jian Z, Zou N . Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients. Front Immunol. 2022; 13:946692. PMC: 9344140. DOI: 10.3389/fimmu.2022.946692. View

12.

Auslander N, Zhang G, Lee J, Frederick D, Miao B, Moll T . Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018; 24(10):1545-1549. PMC: 6693632. DOI: 10.1038/s41591-018-0157-9. View

13.

Jiang T, Nam D, Ram Z, Poon W, Wang J, Boldbaatar D . Clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2020; 499:60-72. DOI: 10.1016/j.canlet.2020.10.050. View

14.

Zhu Y, Knolhoff B, Meyer M, Nywening T, West B, Luo J . CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014; 74(18):5057-69. PMC: 4182950. DOI: 10.1158/0008-5472.CAN-13-3723. View

15.

He Y, Jiang Z, Chen C, Wang X . Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018; 37(1):327. PMC: 6310928. DOI: 10.1186/s13046-018-1002-1. View

16.

Dwivedi P, Greis K . Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Exp Hematol. 2016; 46:9-20. PMC: 5241233. DOI: 10.1016/j.exphem.2016.10.008. View

17.

Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout S . Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol. 2019; 9:2909. PMC: 6297829. DOI: 10.3389/fimmu.2018.02909. View

18.

Karagiannidis I, Salataj E, Egal E, Beswick E . G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation. Cytokine. 2021; 142:155479. PMC: 8044051. DOI: 10.1016/j.cyto.2021.155479. View

19.

Ni X, Wu W, Sun X, Ma J, Yu Z, He X . Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against -null glioblastoma. Sci Adv. 2022; 8(27):eabl5165. PMC: 9269888. DOI: 10.1126/sciadv.abl5165. View

20.

Fleischman A, Maxson J, Luty S, Agarwal A, Royer L, Abel M . The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013; 122(22):3628-31. PMC: 3837511. DOI: 10.1182/blood-2013-06-509976. View